Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY736 in Pemphigus Vulgaris
NCT01930175Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2013
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of ianalumab in pemphigus vulgaris (PV) (3 arms), sponsored by Novartis. Primary endpoint: Pemphigus Disease Area Index at Week 12. Started Dec 2013; status: terminated.
02
Drugs
ianalumab
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on NCT01930175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01930175.